

Obsessive-Compulsive Disorder

Hassan I. Osman*

h.osman@napata.edu.sd

Department of Psychiatry, Medicine Program, Napata College, Khartoum North, Khartoum, Sudan

Abstract

Introduction: Obsessive-Compulsive Disorder is a highly-disabling mental illness that results in the suffering of many individuals around the world. In this article, the disorder is fully looked into: how it occurs, its pathophysiology, its treatment, and the suggested future advances in the management and study of this disorder. **Research Methodology:** A number of search engines (Google Scholar, PubMed, google.com, etc.) were searched with the aforementioned keywords. This resulted in a plethora of results. These were, in turn, filtered through the known criteria regarding their eligibility for usage in review articles. Some sources were inaccessible and were, ergo, excluded from being used here. Moreover, other results were found to be published in predatory journals. Duplicate findings were, of course, eliminated. Following this, the results were filtered based on their relevance to the topic of the article. The data included here was revised and found to be eligible for use and then, and only then, were they included in this article.

Keywords: OCD; Obsessive-Compulsive Disorder; Neuropsychiatry;

Introduction

The Diagnostic and Statistical Manual of Mental Disorders (DSM-5) categorizes OCD (Obsessive-Compulsive Disorder) under 'Obsessive-Compulsive and Related Disorders' (ORCD) (1) and defines it as 'characterized by the presence of obsessions and/or compulsions' (1). ORCD is highly prevalent with 9.5% of the population suffering from it (2). Around 58% of those suffering from OCD will suffer from another one of the ORCDs (3). OCD is, by no means, a newly discovered illness, despite our understanding of it evolving. In fact, OCD has been discussed in religious texts dating at least as far back as the 17th century (4). It is, according to the World Health Organization (WHO), one of the most disabling disorders we know of (5). It is the 4th most common mental disorder, greatly disturbing patient's quality of life through disabling them from conducting their daily activities (6,7). CY-BOCS can be used to assess the severity of OCD (8–10). Considerable evidence exists supporting the hypothesis that anxiety and OCD share a dopaminergic mechanism of action; this possibly justifies why they present together in some instances (11–15). Despite this, the evidence for dopaminergic dysfunction in other disorders, such as tic disorders is far greater than that in OCD. However, given the high co-morbidity between the two, there is reason to believe that our understanding of the dopaminergic dysfunction in tic disorders may play a role in our understanding of OCD

(16).

Non-human primates have exhibited symptoms of OCD and, ergo, manifested themselves as an excellent system for study of the disorder and the its associated cognitive-motor dysfunctions (17–21). The close evolutionary adjacency to humans as well as their overall cognitive and emotional abilities aids greatly in translating findings to humans (22–25). It has been suggested that there exists a correlation between a history of OCD and a number of psychiatric disorders (26–34). Similarities encompassing impulse control disorders (ICDs) and OCD highly suggest the possibility of them being co-morbid (35). OCD is a medical disorder that, in addition to being highly debilitating, is of significant economic burden, as proven in 2023 study (36); further increasing the necessity of the publication of works such as this.

Research Methodology:

A number of online search engines (Google Scholar, PubMed, google.com, etc.) were searched with the aforementioned keywords. This resulted in a plethora of results. These were, in turn, filtered through the known criteria regarding their eligibility for usage in review articles. Some sources were inaccessible and were, ergo, excluded from being used here. Moreover, other results were found to be published in ‘predatory’ journals with poor records and, as a result, also excluded. Duplicate findings were, of course, eliminated. Following this, the results were filtered based on their relevance to the topic of the article. The data included here was revised and found to be eligible for use and then, and only then, were they included in this article.

Clinical presentation and diagnostic modalities:

An excellent summarization of OCD symptoms exists which states that OCD symptoms can be divided into 1) contamination fears and obsessive cleaning, 2) obsessive thoughts about causing harm and compulsive checking rituals, 3) obsessions with symmetry and compulsive ordering, and 4) obsessions relating to the unwarranted collection of objects and hoarding (37).

Many clinical presentations exist in regards to OCD and is, in a number of instances associated with other disorders, such as pathological gambling (PG). Many times, behavioral flexibility issues are noted during the examination. A possible account for these associations may be justified in the neural associations responsible for the reward-learning mechanism being faulty (38).

No laboratory investigations are diagnostic of OCD.

A study reported that as much as 69% of patients presenting with OCD presented with other psychiatric comorbidities, mood disorders and anxiety disorders were the most common at 48% and 32%, respectively (39). More data illustrated a lifetime comorbidity of major depressive disorder (MDD) in 50%, social phobia in 26%, specific phobia in 26%, generalized anxiety disorder (GAD) in 24%, dysthymia in 23%, and psychotic disorder in 4% (28). Another study reported findings that indicate higher rates of symptoms being in correlation with increase in depression severity (40).

Whether or not the associated comorbidities are to be considered primary or secondary to OCD is still a topic of controversy (41). A suggestion has been made to solve this conundrum; that is, to introduce comorbidity as a sub-classification of OCD (42). A Swedish study found that ‘lifetime history of GAD, psychotic disorder, and sub-stance abuse were related to worse prognosis of OCD’ (41); the same study also illustrated how an increase in comorbid conditions is inversely proportional to likelihood of recovery from OCD.

OCD can, as aforementioned, co-occur with a number of psychiatric illnesses. For example, Bipolar disorder (BD). When this happens, it has been found that the symptomatology of OCD does not differ as opposed to individuals suffering from OCD without BD (43). In fact, the comorbidity rate is between 11-21% (44).

Other instances in which OCD may present are during the perinatal period. Studies indicate between 2.2% and 16.9% of women experience OCD in the post-partum (45,46) This period has been identified as one in which

there exists an increased vulnerability to onset or exacerbation of OCD (47), this was found to be more so in women (48). These usually have a theme of ensuring the infant's safety and/or preventing harm (47,49,50). Obsessive symptoms of a sexual and/or violent/harmful nature seem to become manifest in OCD patients going through post-partum as opposed to during pregnancy or any other point in life (51). The characteristic OCD symptoms (those regarded with cleanliness) seem to occur less frequently during the post-partum period (47).

In so far as the co-occurrence between OCD and schizophrenia (in terms of onset) are concerned, 40% of patients reported the obsessive symptoms manifesting prior to psychosis, another 40% reported them occurring following them, and the remaining 20% reported them occurring concurrently (52). Moreover, 12-14% of schizophrenics meet the diagnostic criteria for OCD (52).

Genetic and Neurological Pathophysiology of OCD:

Work by Gasso and colleagues (53) revealed a total of 6 polymorphisms in pediatric individuals with OCD. These were SLC1A1 rs3087879, SLC6A3 rs4975646, CDH9 rs6885387, DRD3 rs3773679, NGFR rs734194, and rs2072446. There is significant evidence regarding the existence of a correlation between serotonergic imbalance and OCD, namely a polymorphism in 5-HTT (SLC6A4) has been connected to OCD patients (54,55).

Despite the serotonergic disruption seeming rather convincing, it is important to note that it is still based purely on empirical evidence and results that are, at best, controversial (56).

RNA sequencing is one of the more modern methodologies used to assess the roles neurons and astrocytes play in disorders pertaining to the brain (57).

In so far as pediatric patients are concerned, there is sufficient reason to believe that alterations to the corpus callosum, cingulum, arcuate fasciculus, uncinate fasciculus, inferior longitudinal fasciculus, superior longitudinal fasciculus, inferior fronto-occipital fasciculus, corticospinal tract, forceps minor and major, and the cerebellum are to be associated with signs and symptoms of obsessive-compulsive disorder (6). It seems highly plausible that these are structural phenotypes of the aforementioned genetic variant (6,53)

Furthermore, glutamate was found in high concentrations in OCD patient's Cerebro-Spinal Fluid (CSF) (58,59). This is of importance as a number of studies have found an association between polymorphisms in the genes SAPAP3 and SLC1A1 and OCD (60–62).

Researchers from China compared the gray and white matters of the brains of rhesus monkeys that exhibited sequential motor behaviors (SMBs) with monkeys that did not exhibit SMBs and found that the fractional anisotropy (FA) value of the corpus callosum (CC) was found to be lower in monkeys exhibiting SMBs (17). Certain imaging modalities seem to possibly be of immense use in the near future when it comes to diagnosing OCD (63); namely, support-vector machine (SVM) model of combined functional Magnetic Resonance Imaging (fMRI) is promising as of this writing.

A recently conducted study found that alterations in the connections consisting the subcortical-cerebellum network as well as 'individualized structural covariance aberrance' being characteristic of OCD (64). These are significant findings as they immensely aid in increasing our understanding of the taxonomy of OCD.

In addition to the aforementioned, involvement of the cortico-striato-thalamo-cortical (CSTC) pathways, limbic regions as well as the reward circuit seem possible (65–69)

Imaging indicates the involvement of the cerebellum, parietal cortex and limbic cortex (35,70). Involvement in these areas can result in 'over-valuation of ideas with inhibited behavioral control' (35).

Another interesting finding in regards to imaging suggests that patients with poor insight into their OCD, when provoked, show changes in activation in circuits responsible for emotional and sensory processing as well as cognitive control (71).

Treatment Protocols:

In summary, treatment of OCD can be divided into: a) Psychotherapy, and b) Pharmacotherapy. Despite these being the guidelines in place, they prove ineffective in ~10% of cases (16).

The first-line psychotherapeutic method is Cognitive-Behavioral Therapy (CBT) including exposure and response prevention, which has been found to be effective in causing a decrease in OCD symptoms (21,72–76). Major issues regarding CBT completion such as its limited accessibility, financial cost, and other factors should be placed into consideration (16,77).

Of the most effective pharmacotherapies is introduction of Selective-Serotonin Reuptake Inhibitors (SSRIs). In fact, they are the first-line pharmacological treatments (72). SSRI treatment (specifically fluoxetine) was found to significantly decrease the time of SMBs in rhesus monkeys (17). Further pharmacological interventions are listed to be introduced, when necessary (such as clomipramine (78) (which is no longer recommended as it may worsen OCD symptoms (16,79)), glutamatergic agents (16) and venlafaxine (80–82)). In a study conducted on human participants, 40% of patients prescribed sertraline experienced remission (83). Published data indicates that 25-60% of individuals suffering from OCD continue to suffer from symptoms following the use of SSRIs and clomipramine (84,85).

As of this writing, a combination of low-dose aripiprazole and risperidone seems to be the most effective in controlling OCD symptoms (16,86–88).

Despite the cumulative efforts set forth, there still remains the issue of ~10% of patients still suffering from disability due to OCD despite correct treatment as per listed guidelines (89).

If the aforementioned treatment modalities fail to bring about desired results, data is suggestive of the use of Deep Brain Stimulation (DBS) as a final treatment modality (90). DBS is to be used on patients meeting certain criteria; these are (91):

- a) Non-response to SSRIs at maximum dosage for at least 12 weeks
- b) A full course of clomipramine (maximum dose) for at least 12 weeks
- c) Addition of an atypical antipsychotic for at least 8 weeks
- d) A full course of CBT
- e) Y-BOCS = at least 28 points
- f) Global Assessment of Functioning (GAF) score of less than 45 points
- g) OCD duration of 5 or more years

DBS has been found to be of immense impact on the quality of life of those who underwent it (92); these results are rather similar to those reported by individuals suffering from Parkinson's when administered the same treatment (93).

There are adverse effects that need to be placed into considerations whenever DBS is being considered for treatment. These side effects include:

- a) Hypomania (16)
- b) Intracranial infection (16)
- c) Intracranial bleeding (16)
- d) Epileptic seizures (16)
- e) Disturbed sleep (16)
- f) Weight gain (16)
- g) An increase in anxiety (16)
- h) Increased risk of suicide (controversial) (94)

Another treatment proposed is transcranial Direct Current Stimulation (tDCS) which showed that anodal pre-

SMA tDCS could possibly improve symptoms of OCD (95). Side effects reported included fatigue, tingling, itching, headache, nausea, and insomnia (96). tDCS has an excellent safety profile; however, ‘the data on the potential efficacy of tDCS in OCD do not currently justify systematically proposing this therapy in resistant or refractory cases’ (16).

Bilateral low-frequency repetitive transcranial magnetic stimulation (rTMS) targeting the supplementary motor area (SMA) was found to reduce OCD symptoms (97).

During follow-up, relapses may, and do, occur. However, 90.3% of pediatric patients seem to improve at the end of 3-year long follow-up (98).

Anti-psychotics such as aripiprazole, risperidone, and haloperidol have all shown positive results when used as adjuvant therapies in the treatment of OCD (35,99). However, there have been cases in which aripiprazole seemed to induce OCD in patients, or at least exacerbate the disorder (100–104). Other antipsychotics such as quetiapine, olanzapine, and paliperidone did not yield such positive results (86,105–107). In fact, olanzapine and clozapine seem to induce OCD symptoms (108). Of course, OCD is, at many times, a comorbidity of conditions which require treatment with antipsychotics, ergo, it is important that iatrogenic causes are excluded (52).

Aripiprazole-induced OCD seems, as per reports, to manifest with hypersexuality, compulsive shopping, and hyperphagia (35).

Not much data exists in regards to the management of anti-psychotic-induced OCD. One study looking into the effects of clozapine-induced OCD reported that introduction of aripiprazole resulted in clinical improvement (109). Similar results were reported in regards to olanzapine-induced OCD being treated using aripiprazole (35).

Data indicated the addition of an SSRI to anti-psychotic treatment may be of benefit in regards to anti-psychotic-induced OCD (110).

In some instances, patients suffering from OCD will not respond to the aforementioned treatment modalities. When that is the case, the patient is deemed either resistant or refractory. A patient is deemed resistant if they have been placed on the highest tolerated dose of SSRIs/clomipramine for at least 12 weeks combined with, at least, 30 hours of Cognitive Behavioral Therapy (CBT) yet exhibited a reduction of under 25% on the Yale Brown Obsessive-Compulsive Scale (Y-BOCS) (16). On the other hand, a patient is deemed suffering from refractory OCD when placed on three antidepressants, with the inclusion of clomipramine, as well as two trials on atypical anti-psychotics (111). Some have proposed the refractory label be reserved to those who do not benefit at all (or even deteriorate) when treatment is administered (112).

As of this, evidence is strongly suggestive of the use of (DBS) in treatment of such patients (113). In fact, a study reported improvement in patient’s YBOCS in the matter of 6-9 weeks following DBS, with an average improvement rate of 45% during the final follow-up session (114).

An experiment took place in which Rituximab was introduced to OCD patients but yielded no significant reduction in symptoms (115).

References:

1. AMERICAN PSYCHIATRIC ASSOCIATION. DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS. FIFTH. Washington, DC. London, England: American Psychiatric Publishing; 2013.
2. Carmi L, Brakoulias V, Arush O, Cohen H, Zohar J. A pro-spective clinical cohort-based study of the prevalence of OCD, obsessive compulsive and related disorders, and tics in families of patients with OCD. *BMC Psychiatry*. 2022;22(1):190.
3. du Toit P, van Kradenburg J, Niehaus D, Stein D. Comparison of obsessive-compulsive disorder patients with and without comorbid putative obsessive-compulsive spectrum disorders using a structured clinical interview. *Compr Psychiatry*. 2001;42(4):291–300.

4. Stanford Medicine [Internet]. [cited 2024 Mar 15]. Obsessive-Compulsive and Related Disorders. Available from: <https://med.stanford.edu/ocd/treatment/history.html>
5. Murray C LA. The global burden of diseases: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Boston, MA: Harvard School of Public Health; 1996. 325 p.
6. Haghshomar M, Peyman S, Parnian M, Anthony S, Mojtaba J. White matter abnormalities in paediatric obsessive – compulsive disorder : a systematic review of diffusion tensor imaging studies. *Brain Imaging and Behavior*. 2023;17:343–66.
7. Ferreira S, Pêgo JM, Morgado P. A systematic review of behavioral, physiological, and neurobiological cognitive regulation alterations in obsessive-compulsive disorder. *Brain Sciences*. 2020;
8. Kaufman J, Birmaher B, Brent D, Al. E. Schedule for Affective Disorders and Schizo- phrenia for School- Age Children—Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. *J Am Acad Child Adolesc Psychiatry*. 1997;36(7):980–8.
9. Kaufman J, Birmaher B, Brent D, Ryan N, Rao U. K-Sads-Pl. *J Am Acad Child Adolesc Psychiatry*. 2000;39(10):1208.
10. Scahill L, Riddle M, McSwiggin-Hardin M, Al. E. Children’s Yale–Brown Obsessive Compulsive Scale: reliability and validity. *J Am Acad Child Adolesc Psychiatry*. 1997;36(6):844–52.
11. Rosenkranz J, Grace A. Cellular mechanisms ofinfralimbic and prelimbic prefrontal cortical inhibition and dopaminergic modulation of basolateral amygdala neurons in vivo. *J Neurosci*. 2002;22:324–37.
12. Denys D, Zohar J, Westenberg H. The role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence. *J Clin Psychiatry*. 2004;65:11–7.
13. Huey E, Zahn R, Krueger F, Moll J, Kapogiannis D, Wassermann E, et al. A psychological and neuroanatomical model of obsessive-compulsive disorder. *J Neuropsychiatry Clin Neurosci*. 2008;20:390–408.
14. Taj M, Viswanath B, Purushottam M, Kandavel T, Janardhan Reddy Y, Jain S. DRD4 gene and obsessive compulsive disorder: do symptom dimensions have specific genetic correlates? *Prog Neuropsychopharmacol Biol Psychiatry*. 2013;41:18–23.
15. Stein D. Obsessive-compulsive disorder. *Lancet*. 2002;360:397–405.
16. Swierkosz-lenart K, Flores J, Dos A, Elowe J, Clair A hélène, Bally JF, et al. Therapies for obsessive-compulsive disorder : Current state of the art and perspectives for approaching treatment-resistant patients. *Frontiers in Psychiatry*. 2023;(February):1–9.
17. Xu S, Wei Q, Zhang X, Li Y, Liao B, Yuan C, et al. Rhesus minkeys exhibiting spontaneous ritualistic behaviors resembling obsessive-compulsive disorder. *National Science Review*. 2023;10.
18. Shima K, Isoda M, Mushiake H, Al. E. Categorization of be- havioural sequences in the prefrontal cortex. *Nature*. 2007;445:315–8.
19. Xie Y, Hu P, Li J, Al. E. Geometry of sequence working memory in macaque prefrontal cortex. *Science*. 2022;375:632–9.
20. Chamberlain S, Fineberg N, Blackwell A, Al. E. Motor inhibition and cognitive flexibility in obsessive-compulsive disorder and trichotillomania. *Am J Psychiatry*. 2006;163:1282–4.
21. Stein D, Costa D, Lochner C, Miguel E, Reddy Y, Shavitt R, et al. Obsessive- compulsive disorder. *Nat Rev Dis Primers*. 2019;5(52).
22. Bernardi S, Salzman C. The contribution of nonhuman primate research to the understanding of emotion and cognition and its clinical relevance. *Proc Natl Acad Sci USA*. 2019;116:26305–12.
23. Ferretti V, Papaleo F. Understanding others: emotion recognition in humans and other animals. *Genes Brain Behav*. 2019;18:e12544.
24. Izpisua Belmonte J, Callaway E, Caddick S, et.al. Brains, genes, and primates. *Neuron*. 2015;86:617–31.
25. Jennings C, Landman R, Zhou Y, Al. E. Opportunities and challenges in modeling human brain disorders in transgenic primates. *Nat Neurosci*. 2016;19:1123–30.

26. Stein D, Costa D, Lochner C, Al. E. Obsessive–compulsive disorder. *Nat Rev Dis Primers*. 2019;5(1):1–21.
27. Karno M, Golding J, Sorenson S, Burnam M. The epidemiology of obsessive-compulsive disorder in five US communities. *Arch Gen Psychiatry*. 1988;45(12):1094–9.
28. Brakoulias V, Starcevic V, Belloch A, Al. E. Comorbidity, age of onset and suicidality in obsessive-compulsive disorder (OCD): an international collaboration. *Compr Psychiatry*. 2017;76:79–86.
29. Hofmeijer-Sevink M, van Oppen P, van Megen H, Al. E. Clinical relevance of comorbidity in obsessive compulsive disorder the Netherlands OCD Association study. *J Affect Disord*. 2013;150(3):847–54.
30. Denys D, Tenney N, van Megen H, de Geus F, Westenberg H. Axis I and II comorbidity in a large sample of patients with obsessive-compulsive disorder. *J Affect Disord*. 2004;80(2–3):155–62.
31. Yaryura-Tobias J, Grunes M, Todaro J, McKay D, Neziroglu F, Stockman R. Nosological insertion of axis I disorders in the etiology of obsessive-compulsive disorder. *J Anxiety Disord*. 2000;14(1):19–30.
32. Pinto A, Mancebo M, Eisen J, Pagano M, Rasmussen S. The Brown Longitudinal Obsessive Compulsive Study: clinical features and symptoms of the sample at intake. *J Clin Psychiatry*. 2006;67(5):703–11.
33. Ruscio A, Stein D, Chiu W, Kessler R. The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. *Mol Psychiatry*. 2010;15(1):53–63.
34. Fineberg N, Hengartner M, Bergbaum C, Gale T, Rossler W, Angst J. Lifetime comorbidity of obsessive-compulsive disorder and sub-threshold obsessive-compulsive symptomatology in the community: impact, prevalence, socio-demographic and clinical characteristics. *Int J Psychiatry Clin Pract*. 2013;17(3):188–96.
35. Burk BG, Digiacoimo T, Polancich S. Antipsychotics and obsessive – compulsive disorder/ obsessive – compulsive symptoms : A pharmacovigilance study of the FDA adverse event reporting system. *Acta Psychiatrica Scandinavica*. 2023;148(December 2022):32–46.
36. Kochar N, Ip S, Vardanega V, Sireau NT, Fineberg NA. A cost-of-illness analysis of the economic burden of obsessive-compulsive disorder in the United Kingdom. *Compr Psychiatry* [Internet]. 2023;127(September):152422. Available from: <https://doi.org/10.1016/j.comppsy.2023.152422>
37. Stein DJ. Obsessive-compulsive disorder. *The Lancet*. 2002;360(9330):397–405.
38. Suzuki S, Zhang X, Dezfouli A, Braganza L, Fulcher BD, Parkes L, et al. Individuals with problem gambling and obsessive-compulsive disorder learn through distinct reinforcement mechanisms. *PLOS Biology*. 2023;1–26.
39. Sharma E, Sharma L, Balachander S, Al. E. Comorbidities in obsessive-compulsive disorder across the lifespan: a systematic review and meta-analysis. *Front Psych*. 2021;12(703701).
40. Baer L, Trivedi M, Huz I, Rush A, Wisniewski S, Fava M. Prevalence and impact of obsessive-compulsive symptoms in depression: a STAR*D report. *J Clin Psychiatry*. 2015;76(12):1668–74.
41. Klenfeldt IF, Skoog I, Skoog G, Skoog J. The natural history of lifetime psychiatric disorders in patients with obsessive-compulsive disorder followed over half a century. *Acta Psychiatr Scand*. 2024;149(January):284–94.
42. Nestadt G, Di C, Riddle M. Obsessive-compulsive disorder: subclassification based on co-morbidity. *Psychol Med*. 2009;39(9):1491–501.
43. Prisco M De, Tapoi C, Oliva V, Possidente C, Strumila R, Takami C, et al. Clinical features in co-occurring obsessive-compulsive disorder and bipolar disorder : A systematic review and meta-analysis. *European Neuropsychopharmacology*. 2024;80(October 2023):14–24.
44. Amerio A, Stubbs B, Odone A, Tonna M, Marchesi C, Ghaemi S. The prevalence and predictors of comorbid bipolar disorder and obsessive-compulsive disorder: a systematic review and meta-analysis. *J Affect Disord*. 2015;186:99–109.
45. Fairbrother N, Janssen P, Antony A, Tucker E, Young A. Perinatal anxiety disorder prevalence and incidence. *J Affect Disord*. 2016;200:148–155.
46. Fairbrother N, Collardeau F. High prevalence of perinatal-occurring obsessive-compulsive disorder: Reply to Di Giacomo et al. *J Clin Psych*. 2021;82(6):37482.
47. Mulcahy M, Long C, Morrow T, Galbally M, Rees C, Anderson R. Consensus recommendations for the

assessment and treatment of perinatal obsessive – compulsive disorder (OCD): A Delphi study. *Archives of Women's Mental Health*. 2023;26:389–99.

48. Russell E, Fawcett J, Mazmanian D. Risk of obsessive-compulsive disorder in pregnant and postpartum women: A meta-analysis. *J Clin Psychiatry*. 2013;74(4):377–385.
49. Abramowitz J, Schwartz S, Moore K, Luenzmann K. Obsessive-compulsive symptoms in pregnancy and the puerperium: A review of the literature. *J Anxiety Disord*. 2003;17(4):461–478.
50. McGuinness M, Blissett J, Jones C. OCD in the perinatal period: Is postpartum OCD (ppOCD) a distinct subtype? A review of the literature. *Behav Cogn Psychother*. 2011;39(2):285–310.
51. Starcevic V, Eslick G, Viswasam K, Berle D. Symptoms of obsessive-compulsive disorder during pregnancy and the post-partum period: A systematic review and meta-analysis. *Psychiatr Q*. 2020;91(4):965–981.
52. Sharma L, Reddy Y. Obsessive-compulsive disorder comorbid with schizophrenia and bipolar disorder. *Indian J Psychiatry*. 2019;61(Suppl 1):S140–8.
53. Gassó P, Ortiz AE, Mas S, Morer A, Calvo A, Bargalló N, et al. Association between genetic variants related to glutamatergic, dopaminergic and neurodevelopment pathways and white matter microstructure in child and adolescent patients with obsessive-compulsive disorder. *Journal of Affective Disorders*. 2015;186:284–92.
54. Saiz P, Garcia-Portilla M, Arango C, Morales B, Bascaran M, Martinez-Barrondo S, et al. Association study between obsessive-compulsive disorder and serotonergic candidate genes. *Prog Neuropsychopharmacol Biol Psychiatry*. 2008;32:765–70.
55. Greenberg B, Benjamin J, Martin J, Keuler D, Huang S, Altemus M, et al. Delayed obsessive-compulsive disorder symptom exacerbation after a single dose of a serotonin antagonist in fluoxetine-treated but not untreated patients. *Psychopharmacology*. 1998;140:434–44.
56. Pittenger C. Pharmacotherapeutic strategies and new targets in OCD. *Curr Top Behav Neurosci*. 2021;49:331–84.
57. Kelley KW, Nakao-inoue H, Molofsky A V, Michael C, Francisco S, Francisco S, et al. Variation among intact tissue samples reveals the core transcriptional features of human CNS cell classes. *Nat Neurosci*. 2018;21(9):1171–84.
58. Chakrabarty K, Bhattacharyya S, Christopher R, Khanna S. Glutamatergic dysfunction in OCD. *Neuropsychopharmacology*. 2005;30:1735–40.
59. Bhattacharyya S, Khanna S, Chakrabarty K, Mahadevan A, Christopher R, Shankar S. Anti-brain autoantibodies and altered excitatory neurotransmitters in obsessive-compulsive disorder. *Neuropsychopharmacology*. 2009;34:2489–96.
60. Welch J, Lu J, Rodriguiz R, Trotta N, Peca J, Ding J, et al. Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice. *Nature*. 2007;448:894–900.
61. Samuels J, Wang Y, Riddle M, Greenberg B, Fyer A, McCracken J, et al. Comprehensive family-based association study of the glutamate transporter gene SLC1A1 in obsessive-compulsive disorder. *Am J Med Genet B Neuropsychiatr Genet*. 2011;156B:472–7.
62. Bozorgmehr A, Ghadirivassfi M, Shahsavand Ananloo E. Obsessive-compulsive disorder, which genes? Which functions? Which pathways? An integrated holistic view regarding OCD and its complex genetic etiology. *J Neurogenet*. 2017;31:153–60.
63. Huang F fang, Yang X yun, Luo J, Yang X jie, Meng F qiang, Wang P chong, et al. Functional and structural MRI based obsessive-compulsive disorder diagnosis using machine learning methods. *BMC Psychiatry*. 2023;23:792.
64. Han S, Xu Y, Guo H rong, Fang K, Wei Y, Liu L. Resolving heterogeneity in obsessive – compulsive disorder through individualized differential structural covariance network analysis. *Cerebral Cortex*. 2023;33(April 2022):1659–68.
65. Gasso P, Ortiz A, Mas S, Al. E. Association between genetic variants related to glutamatergic, dopaminergic and neurodevelopment pathways and white matter microstructure in child and adolescent patients with obsessive-compulsive disorder. *J Affect Disord*. 2015;186:284–92.

66. Zhang S, Jiang W, Tang X, Al. E. Association study of dopamine transporter gene (DAT1) variable tandem repeat sequence (VNTR) with obsessive-compulsive disorder in Chinese Han Population. *Int J Clin Exp Med*. 2015;8(3):4606–10.
67. Mak L, Streiner D, Steiner M. Is serotonin transporter poly- morphism (5-HTTLPR) allele status a predictor for obsessive- compulsive disorder? A meta-analysis. *Arch Womens Ment Health*. 2015;18(3):435–45.
68. Cengiz M, Okutan S, Bayoglu B, Sakalli Kani A, Bayar R, Kocabasoglu N. Genetic polymorphism of the serotonin trans- porter gene, SLC6A4 rs16965628, is associated with obsessive compulsive disorder. *Genet Test Mol Biomarkers*. 2015;19(5):228–34.
69. Rodriguez C, Kegeles L, Levinson A, Al. E. In vivo effects of ketamine on glutamate-glutamine and gamma-aminobutyric acid in obsessive-compulsive disorder: proof of concept. *Psychiatry Res*. 2015;233(2):141–7.
70. Hazari N, Narayanaswamy J, Venkatasubramanian G. Neuro- imaging findings in obsessive-compulsive disorder: a narrative review to elucidate neurobiological underpinnings. *Indian J Psychiatry*. 2019;61:S9–29.
71. Broekhuizen A, Vriend C, Wolf N, Koenen EH, Oppen P Van, Balkom AJLM Van, et al. Poor Insight in Obsessive-Compulsive Disorder as a Multifaceted Phenomenon : Evidence From Brain Activation During Symptom Provocation. *Biological Psychiatry: Cognitive Neuroscience and Neuroimaging*. 2023;8(11):1135–44.
72. American Psychiatric Association. Practice guideline for the treatment of patients with obsessive-compulsive disorder. Arlington, VA: American Psychiatric Association; 2007.
73. Reid J, Laws K, Drummond L, Vismara M, Grancini B, Mpavaenda D, et al. Cognitive behavioural therapy with exposure and response prevention in the treatment of obsessive-compulsive disorder: a systematic review and meta-analysis of randomised controlled trials. *Compr Psychiatry*. 2021;106(152223).
74. Olatunji B, Davis M, Powers M, Smits J. Cognitive-behavioral therapy for obsessive- compulsive disorder: a meta-analysis of treatment outcome and moderators. *J Psychiatr Res*. 2013;47:33–41.
75. Öst L, Havnen A, Hansen B, Kvale G. Cognitive behavioral treatments of obsessive- compulsive disorder. A systematic review and meta-analysis of studies published 1993- 2014. *Clin Psychol Rev*. 2015;40(156):156–69.
76. Rosa-Alcázar A, Sánchez-Meca J, Gómez-Conesa A, Marín-Martínez F. Psychological treatment of obsessive-compulsive disorder: a meta-analysis. *Clin Psychol Rev*. 2008;28(13):10–25.
77. Mancebo M, Eisen J, Sibrava N, Dyck I, Rasmussen S. Patient utilization of cognitive-behavioral therapy for OCD. *Behav Ther*. 2011;42:399–412.
78. The Clomipramine Collaborative Study Group. Clomipramine in the treatment of patients with obsessive-compulsive disorder. *Arch Gen Psychiatry*. 1991;48:730–8.
79. Grover S, Hazari N, Chakrabarti S, Avasthi A. Relationship of obsessive compulsive symptoms/disorder with clozapine: a retrospective study from a multispeciality tertiary care centre. *Asian J Psychiatr*. 2015;15:56–61.
80. Katzman M, Bleau P, Blier P, Chokka P, Kjernisted K, Van Ameringen M, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. *BMC Psychiatry*. 2014;14.
81. Albert U, Aguglia E, Maina G, Bogetto F. Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study. *J Clin Psychiatry*. 2002;63:1004–9.
82. Hollander E, Friedberg J, Wasserman S, Allen A, Birnbaum M, Koran L. Venlafaxine in treatment-resistant obsessive compulsive disorder. *J Clin Psychiatry*. 2003;64:546– 50.
83. Skarphedinsson G, Weidle B, Thomsen P, Al. E. Continued cognitive behavior therapy vs sertraline for children and adolescents with obsessive-compulsive disorder that were non-responders to cognitive behavior therapy—a randomized controlled trial. *Eur Child Adolesc Psychiatry*. 2015;24(5):591–602.
84. Hirschtritt M, Bloch M, Mathews C. Obsessive-compulsive disorder: advances in diagnosis and treatment. *Jama*. 2017;317(13):1358–67.
85. Pallanti S, Quercioli L. Treatment-refractory obsessive- compulsive disorder: methodological issues,

operational definitions and therapeutic lines. *Prog Neuropsychopharmacol Biol Psychiatry*. 2006;30(3):400–12.

86. Simpson H, Foa E, Liebowitz M, Huppert J, Cahill S, Maher M, et al. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial. *JAMA Psychiatry*. 2013;70:1190–9.
87. Veale D, Miles S, Smallcombe N, Ghezai H, Goldacre B, Hodsoll J. Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis. *BMC Psychiatry*. 2014;14(317).
88. Albert U, Marazziti D, Di Salvo G, Solia F, Rosso G, Maina G. A systematic review of evidence-based treatment strategies for obsessive-compulsive disorder resistant to first-line pharmacotherapy. *Curr Med Chem*. 2018;25:5647–61.
89. Denys D. Pharmacotherapy of obsessive-compulsive disorder and obsessive-compulsive spectrum disorders. *Psychiatr Clin North Am*. 2006;29:553–84.
90. Alonso P, Cuadras D, Gabriëls L, Denys D, Goodman W, Greenberg B, et al. Deep brain stimulation for obsessive-compulsive disorder: a meta-analysis of treatment outcome and predictors of response. *PLoS One*. 2015;10:e0133591.
91. Berlin H, Koran L, Jenike M, Shapira N, Chaplin W, Pallanti S, et al. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. *J Clin Psychiatry*. 2011;72:716–21.
92. Haan S d, Rietveld E, Stokhof M, Denys D. Effects of deep brain stimulation on the lived experience of obsessive-compulsive disorder patients: in-depth interviews with 18 patients. *PLoS One*. 2015;10:e0135524.
93. Schüpbach M, Gargiulo M, Welter M, Mallet L, Béhar C, Houeto J, et al. Neurosurgery in Parkinson disease: a distressed mind in a repaired body? *Neurology*. 2006;66:1811–6.
94. Mar-Barrutia L, Real E, Segalás C, Bertolín S, Menchón J, Alonso P. Deep brain stimulation for obsessive-compulsive disorder: a systematic review of worldwide experience after 20 years. *World J Psychiatry*. 2021;11:659–80.
95. Gowda S, Narayanaswamy J, Hazari N, Bose A, Chhabra H, Balachander S, et al. Efficacy of pre-supplementary motor area transcranial direct current stimulation for treatment resistant obsessive compulsive disorder: a randomized, double blinded, sham controlled trial. *Brain Stimul*. 2019;12:922–9.
96. Poreisz C, Boros K, Antal A, Paulus W. Safety aspects of transcranial direct current stimulation concerning healthy subjects and patients. *Brain Res Bull*. 2007;72:208–14.
97. Hawken E, Dilkov D, Kaludiev E, Simek S, Zhang F, Milev R. Transcranial magnetic stimulation of the supplementary motor area in the treatment of obsessive-compulsive disorder: a multisite study. *Int J Mol Sci*. 2016;17(420).
98. Ivarsson T, Jensen S, Hybel KA, Torp NC, Melin K, Nissen JB, et al. Remission and Relapse Across Three Years in Pediatric Obsessive-Compulsive Disorder Following Evidence-Based Treatments. *Journal of the American Academy of Child & Adolescent Psychiatry*. 2023;1–9.
99. Del Casale A, Sorice S, Padovano A, Al. E. Psychopharmacological treatment of obsessive-compulsive disorder (OCD). *Curr Neuropharmacol*. 2019;17(8):710–36.
100. Desarkar P, Das A, Nizamie S. Aripiprazole-induced obsessive-compulsive disorder: a report of 2 cases. *J Clin Psychopharmacol*. 2007;27(3):305–6.
101. Nafisa D, Kakunje A. Aripiprazole-induced obsessive-compulsive symptoms. *Ind Psychiatry J*. 2022;31(1):158–61.
102. Mouaffak F, Gallarda T, Bayle F, Olie J, Baup N. Worsening of obsessive-compulsive symptoms after treatment with aripiprazole. *J Clin Psychopharmacol*. 2007;27(2):237–8.
103. Gupta P, Gupta R, Balhara Y. Obsessive-compulsive symptoms associated with aripiprazole treatment in bipolar disorder: a case report. *J Clin Psychopharmacol*. 2017;37(1):108–9.
104. Chun L, Chang H, Huang M. Aripiprazole-induced obsessive-compulsive symptoms. *Taiwan J Psychiatry*.

2020;34:47–8.

105. Dold M, Aigner, M, Lanzenberger R KS. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: an update metaanalysis of double-blind, randomized, placebo-controlled trials. *Int J Neuropsychopharmacol*. 2015;18(9):1–11.
106. Sayyah M, Boostani H, Ghaffari S, Hoseini A. Effects of aripiprazole augmentation in treatment-resistant obsessive-compulsive disorder (a double blind clinical trial). *Depress Anxiety*. 2012;29(10):850–4.
107. Storch E, Goddard A, Grant J, Al. E. Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder. *J Clin Psychiatry*. 2013;74(6):e527–32.
108. Fonseka T, Richter M, Muller DJ. Second generation antipsychotic-induced obsessive-compulsive symptoms in schizophrenia: a review of the experimental literature. *Curr Psychiatry Rep*. 2014;16(11):510.
109. Englisch S, Esslinger C, Inta D, Al. E. Clozapine-induced obsessive-compulsive syndromes improve in combination with aripiprazole. *Clin Neuropharmacol*. 2009;32(4):227–9.
110. de Haan L, Linszen D, Gorsira R. Clozapine and obsessions in patients with recent-onset schizophrenia and other psychotic disorders. *J Clin Psychiatry*. 1999;60(6):364–5.
111. Piccinelli M, Pini S, Bellantuono C, Wilkinson G. Effectiveness of drug treatment in OCD: a metanalytic review. *B J P*. 1995;166(82):424–43.
112. Pallanti S, Hollander E, Bienstock C, Koran L, Leckman J, Marazziti D, et al. Treatment non-response in OCD: methodological issues and operational definitions. *Int J Neuropsychopharmacol*. 2002;5:181–91.
113. Beszlej J, Wiczorek T, Kobyłko A, Piotrowski P, Siwicki D, Weiser A, et al. Deep brain stimulation: new possibilities for the treatment of mental disorder. *Psychiatr Pol*. 2019;53:789–806.
114. Acevedo N, Rossell S, Castle D, Groves C, Cook M, McNeill P, et al. Clinical outcomes of deep brain stimulation for obsessive-compulsive disorder: Insight as a predictor of symptom changes. *Psychiatry and Clinical Neurosciences*. 2024;78:131–41.
115. Bejerot S, Sigra S, Welin E, Eklund D, Hyl U. Rituximab as an adjunctive treatment for schizophrenia spectrum disorder or obsessive-compulsive disorder: Two open-label pilot studies on treatment-resistant patients. *Journal of Psychiatric Research*. 2023;158(November 2022):319–29.